

24 January 2025

IXICO plc
("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	%ISC VOTED	VOTES WITHHELD
1	Reports and Accounts	68,485,623	99.95%	31,468	0.05%	68,517,091	73.94	400
2a	Election of Bram Goorden	68,473,140	99.95%	32,668	0.05%	68,505,808	73.93	11,683
2b	Re-election of Grant Nash	68,474,566	99.95%	36,376	0.05%	68,510,942	73.93	6,549
2c	Re-election of Mark Warne	68,473,966	99.95%	36,976	0.05%	68,510,942	73.93	6,549
2d	Re-election of Dr Dipti Amin	68,470,760	99.95%	35,048	0.05%	68,505,808	73.93	11,683
2e	Re-election of Kate Rogers	68,475,894	99.95%	35,048	0.05%	68,510,942	73.93	6,549
3	Re-appointment of Moore Kingston Smith Auditors	68,473,359	99.95%	36,401	0.05%	68,509,760	73.93	7,731
4	Allotment of Securities	68,475,089	99.94%	41,502	0.06%	68,516,591	73.94	900
5	* Disapply Pre-Emption Provisions	68,399,849	99.83%	116,742	0.17%	68,516,591	73.94	900
6	* Issue of 'value multiple and exit' share options to Bram Goorden, CEO, and Grant Nash, CFO.	68,352,128	99.76%	163,273	0.24%	68,515,401	73.94	2,090
7	* To adopt new Articles of Association for the Company	68,473,361	99.94%	43,830	0.06%	68,517,191	73.94	300

* Special Resolutions

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.

Further information:

IXICO plc
Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0) 20 3763 7499

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks/Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)

+44 (0) 20 7220 0500

About IXICO www.IXICO.com

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access

technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGPKQBDQBKDDDB